Clinical Momentum OS Therapies is a clinical stage biotechnology company advancing OST-HER2 through a PhIIb trial with early signals of improved event-free survival and potential overall survival benefit, presenting a near-term opportunity for strategic collaboration or co-development discussions with partners focused on osteosarcoma and HER2-expressing cancers.

Platform Synergy The company operates two platform approaches OST-HER2 and OST-tADC, enabling conversations with potential partners in immunotherapy and tumor debulking space, as well as potential licensing or collaboration deals around novel payload delivery in acidic tumor microenvironments.

Strategic Advisors Appointment of a high-profile Chief Medical Advisor signals credibility in clinical development and can open doors for tiered partnerships with biotech investors and large pharma seeking oncology expertise and advisory involvement.

Funding Readiness With current funding of 37M and a recent convertible note offering in progress, there are clear revenue and financing touchpoints for investors and strategic financiers, including potential co-investment or bridge financing discussions aligned with clinical milestones.

Market & Engagement Active participation in industry events and partnerships for OST-HER2 commercialization in the US through EVERSANA, plus ongoing outreach across conferences, positions OS Therapies for visibility with potential licensing, distribution, or co-promotion opportunities as the program progresses.